SARS-CoV-2 SP modRNA LNP vaccine BNT162a1

**Semantic type:** Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance

**Definition:** A formulation consisting of lipid nanoparticle (LNP) encapsulating nucleoside-modified messenger RNA (modRNA) encoding the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (SP), with potential immunizing and anti-COVID-19 activities. Upon injection of SARS-CoV-2 SP modRNA LNP vaccine BNT162a1, the LNPs bind to the plasma membrane of nearby cells and release SARS-CoV-2 SP mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce SARS-CoV-2 SP. This may stimulate the immune system to induce an antibody and T-cell-mediated immune response. This may provide active immunization against SARS-CoV-2 infection. SP, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.

**Synonyms:** - BNT 162a1 - BNT-162A1 - BNT-162a1 - BNT1162a1 SARS-CoV-2 Vaccine - BNT162a1 - BNT162a1 COVID-19 Vaccine